Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
MTHFR, TYMS and SLCO1B1 polymorphisms and adverse liver effects of methotrexate in rheumatoid arthritis
Luleå University of Technology, Department of Health Sciences, Health, Medicine and Rehabilitation. Department of Medical Sciences, Rheumatology, Uppsala University, Sweden.ORCID iD: 0000-0001-5313-7981
Department of Medical Sciences, Rheumatology, Uppsala University, Sweden.
Department of Medical Sciences, Clinical Pharmacology & Science for Life Laboratory, Uppsala University, Sweden.
Department of Medical Sciences, Clinical Pharmacology & Science for Life Laboratory, Uppsala University, Sweden.
Show others and affiliations
2020 (English)In: Pharmacogenomics (London), ISSN 1462-2416, E-ISSN 1744-8042, Vol. 21, no 5, p. 337-346Article in journal (Refereed) Published
Abstract [en]

Aims: To investigate whether variants of MTHFR, TYMS and SLCO1B1 are associated with alanine aminotransferase (ALT) elevation in rheumatoid arthritis patients starting methotrexate (MTX).

Patients & Methods: Clinical and laboratory data were collected from the start of MTX treatment. Genotyping of MTHFR, TYMS and SLCO1B1 was performed. Univariate and multiple logistic regression were used for statistical analysis.

Results: 34 out of 369 patients experienced ALT >1.5xULN less than 6 months from start. MTHFR A1298C (rs1801131) was nominally associated with an ALT > 1.5 xULN within 6 months after the start of MTX (OR = 1.7 [95% CI: 1.04–2.9]; p = 0.03), but did not pass correction for multiple testing. A multiple model containing MTHFR 1298C and clinical factors predicted the outcome (C-statistic 0.735). TYMS and SLCO1B1 were not associated with the outcome.

Conclusions: A model containing MTHFR 1298C and clinical factors might predict risk of early ALT elevation.

Place, publisher, year, edition, pages
London: Future Medicine , 2020. Vol. 21, no 5, p. 337-346
Keywords [en]
liver toxicity, methotrexate, MTHFR, rheumatoid arthritis, transaminases, TYMS and SLCO1B1
National Category
Clinical Medicine
Research subject
Medical Science
Identifiers
URN: urn:nbn:se:ltu:diva-78120DOI: 10.2217/pgs-2019-0186PubMedID: 32024416Scopus ID: 2-s2.0-85084192185OAI: oai:DiVA.org:ltu-78120DiVA, id: diva2:1415925
Note

Validerad;2020;Nivå 2;2020-05-11 (alebob)

Available from: 2020-03-20 Created: 2020-03-20 Last updated: 2020-05-12Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records BETA

Sundbaum, Johanna

Search in DiVA

By author/editor
Sundbaum, JohannaWadelius, Mia
By organisation
Health, Medicine and Rehabilitation
In the same journal
Pharmacogenomics (London)
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 12 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf